Physician profile
Casey Clark
NPI 1306340286
$4,817.08
in general payments reported to CMS, 2019-2025
34 companies · $1,834 in 2025
The $1,834 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $110 · 2023: $1,078 · 2024: $1,794 · 2025: $1,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,706.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $931.70 | 2023-2025 | Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $462.48 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $444.61 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $371.83 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $370.90 | 2023-2025 | |
| Novo Nordisk INC | $328.88 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $252.70 | 2023-2025 | Repatha, Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $169.93 | 2022-2024 | Gvoke Hypopen |
| Insulet Corporation | $162.45 | 2023-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $161.00 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $155.40 | 2022-2023 | Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.11 | 2022-2025 | Jardiance |
| Abbott Laboratories | $101.49 | 2024-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $85.40 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $80.98 | 2024-2025 | Fanapt, Hetlioz |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $80.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $72.89 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $72.03 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $46.96 | 2024 | |
| Astellas Pharma US INC | $46.91 | 2023-2024 | Veozah, Myrbetriq |
| Dexcom, INC. | $43.50 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $41.28 | 2023-2025 | Vpriv, Aralast |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.57 | 2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $23.54 | 2025 | Givlaari |
| Boston Scientific Corporation | $23.30 | 2023 | Wavewriter Alpha Prime 16 |
| Gilead Sciences, INC. | $21.99 | 2024 | |
| Phadia US INC. | $19.94 | 2023 | Immunocap |
| Bausch Health US, LLC | $19.22 | 2022 | |
| Verona Pharma, INC. | $17.36 | 2025 | Ohtuvayre |
| Medtronic, INC. | $16.46 | 2023 | Inpen Smart Insulin Delivery System |
| Evoke Pharma, INC. | $15.55 | 2023 | Gimoti |
| Otsuka America Pharmaceutical, INC. | $14.69 | 2023 | Rexulti |
| Grifols USA, LLC | $13.66 | 2023 | Prolastin-C Liquid |
| E.R. Squibb & Sons, L.L.C. | $13.63 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.